Skip to main content

Table 2 Intra- versus intergroup comparison of variables at the baseline versus at 3 months follow-up among the two groups

From: Effect of carvedilol versus nebivolol on insulin resistance among non-diabetic, non-ischemic cardiomyopathy with heart failure

 

G1

G2

Inter-group

Baseline

After 3 months

Baseline

After 3 months

cP

dP

1. HR

102 ± 7

71 ± 5

103 ± 9

70 ± 6

  

 Intragroup t test

aP < 0.001*

bP < 0.001*

0.68

0.55

2. BP

137 ± 7

130 ± 8

135 ± 6

130 ± 9

  

85 ± 9

80 ± 10

32 ± 5

80 ± 6

 Intragroup t test

aP < 0.001*, < 0.001*

bP < 0.001*, < 0.02*

0.21

0.68

3. NYHA

Class I

20 (80%)

19 (76 %)

12 (66.7%)

14 (77.8%)

  

Class II

6 (24%)

6 (24%)

6 (33.3%)

4 (22.2%)

 Intragroup t test

aP = 0.03*

bP = 0.046*

0.85

0.99

4. EF%

39 ± 4.2

42 ± 3.0

38.9 ± 3.2

41.8 ± 3.3

  

 Intragroup t test

aP < 0.001*

bP < 0.001*

0.93

0.84

5. B blocker compliance

24 (96%)

24 (96%)

17 (94%)

17 (94%)

  

 Intragroup t test

aP > 0.99

bP > 0.99

0.99

0.99

6. HbA1c

5.8 ± 0.8

5.9 ± 0.3

5.9 ± 0.6

5.3 ± 0.2

  

 Intragroup t test

aP = 0.76

bP < 0.001*

0.55

< 0.001*

7. Fasting glucose (mg/dl)

102 ± 14

103 ± 9

103 ± 9

97 ± 7

  

 Intragroup t test

aP = 0.73

bP < 0.001*

0.31

0.023*

8. Plasma insulin (lU/ml)

5.3 ± 3.2

5.4 ± 3.9

5.4 ± 4.1

3.5 ± 0.23

  

 Intragroup t test

aP = 0.62

bP = 0.01*

0.92

0.046*

9. HOMA-IR

1.31 ± 0.29

1.37 ± 0.3

1.37 ± 0.3

1.21 ± 0.08

  

 Intragroup t test

aP = 0.41

bP = 0.01*

0.52

0.01*

10. Plasma norepinephrine (pg/ml%)

530 ± 159

436 ± 30

531 ± 171

499 ± 102

  

 Intragroup t test

aP = 0.002*

bP = 0.08

0.98

0.019*

11. Plasminogen activator I (ng/ml)

9.9 ± 3.2

9.8 ± 2.7

10.2 ± 2.5

10.1 ± 3.3

  

 Intragroup t test

aP = 0.37

bP = 0.81

0.74

0.75

  1. HR heart rate, BP blood pressure, HbA1c glycated hemoglobin, HOMA-IR homeostasis model of assessment, NYHA New York Heart Association Classification, EF ejection fraction, G1 group 1, G2 group 2
  2. *P is significant
  3. aP intragroup comparison of group 1
  4. bP intragroup comparison of group 2
  5. cP intragroup comparison of group 1; intergroup comparison of group 1 and group 2 at baseline
  6. dP intergroup comparison of group 1 and group 2 after 3 months